An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 27 Jan 2022
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 21 Jan 2022 Status changed from active, no longer recruiting to completed.
- 24 Sep 2021 Planned End Date changed from 1 Dec 2021 to 30 Dec 2021.
- 24 Sep 2021 Planned primary completion date changed from 1 Dec 2021 to 30 Dec 2021.